Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells

Carcinogenesis

Volumn 26, Issue 5, 2005, Pages 883-891

  Cafforio, Paola ^a   Dammacco, Franco ^a   Gernone, Angela ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CASPASE 3; CASPASE 8; CASPASE 9; CERIVASTATIN; CHOLESTEROL; DOXORUBICIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GUANOSINE TRIPHOSPHATASE; MEVINOLIN; PRAVASTATIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SIMVASTATIN; SQUALENE; CASPASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; MYELOMA CELL; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; B LYMPHOCYTE; CELL MEMBRANE; CYTOSOL; DRUG EFFECT; LEUKEMIA CELL LINE; METABOLISM; MITOCHONDRION; MULTIPLE MYELOMA; PHYSIOLOGY; T LYMPHOCYTE;

APOPTOSIS; B-LYMPHOCYTES; CASPASES; CELL MEMBRANE; CELL PROLIFERATION; CYTOSOL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JURKAT CELLS; MITOCHONDRIA; MULTIPLE MYELOMA; PROTEIN TRANSPORT; RAS PROTEINS; RHO GTP-BINDING PROTEINS; T-LYMPHOCYTES;

EID: 19844367157     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgi036     Document Type: Article

References (51)

1. Endo, A. (1994) The discovery and development of HMG-CoA reductase inhibitors. J. Lipid. Res., 33, 1569-1582.
2. Goldstein, J.S. and Brown, M.S. (1990) Regulation of the mevalonate pathway. Nature, 343, 425-430.
3. Elson, C.E., Peffley, D.M., Hentosh, P. and Mo, H. (1999) Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med., 221, 294-311.
4. 1 to S phase transition in mouse fibroblasts. Oncogens, 13, 1991-1999.
5. Yoshida, Y., Kawata, M., Katayama, M., Horiuchi, H., Kita, Y. and Takai, Y. (1991) A geranyl-geranyltransferase for rhoA p21 distinct from the farnesyltransferase for ras p21S. Biochem. Biophys. Res. Commun., 175, 720-728.
6. Kobashigawa, J.A., Katznelson, S., Laks, H., Johnson, J.A., Yeatman, L., Wang, X.M., Chia, D., Terasaki, P.I., Sabad, A., Cogert, G.A., Trosian, K., Hamilton, M.A., Moriguchi, J.D., Kawata, N., Hage, A., Drinkwater, D.C. and Stevenson, L.W. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med., 333, 621-627.
7. Katznelson, S. and Kobashigawa, J.A. (1995) Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int., 48, S112-S115.
8. Kurakata, S., Kada, M., Shimada, Y., Kamai, T. and Namoto, K. (1996) Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacol., 34, 51-61.
9. Rudich, S.M., Mongini, P.K.A., Perez, R.V. and Katznelson, S. (1998) HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant. Proc., 30, 992-995.
10. Kwak, B., Mulhaupt, F., Myit, S. and Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med., 6, 1399-1402.
11. Romano, M., Diomede, L., Sironi, M., Massimiliano, L., Sottocorno, M., Polentarutti, N., Guglielmotti, A., Albani, D., Bruno, A., Fruscella, P., Salmona, M., Vecchi, A., Pinza, M. and Mantovani, A. (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest., 80, 1095-1100.
12. Inoue, I., Goto, S., Mizotani, K., Awata, T., Mastunaga, T., Kawai, S., Nakajima, T., Hokari, S., Komoda, T. and Katayama, S. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22 phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci., 67, 867-876.
13. Knapp, A.C., Huang, J., Starling, G. and Kiener, P.A. (2000) Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis, 152, 217-227.
14. Sonoda, Y., Gotow, T., Kuriyama, M., Nakahara, K., Arimura, K. and Osame, M. (1994) Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve, 17, 891-897.
15. Mutoh, T., Kumano, T., Nakagawa, H. and Kuriyama, M. (1999) Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS, 444, 85-89.
16. van Vliet, A.K., Negre-Aminou, P., van Thiel, G.C., Bolhuis, P.A. and Cohen, L.H. (1996) Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem. Pharmacol., 52, 1387-1392.
17. Thompson, P.D., Clarkson, P. and Karas, R.H. (2003) Statin-associated myopathy. JAMA, 289, 1681-1690.
18. Keyomarsi, K., Sandoval, L., Band, V. and Pardee, A.B. (1991) Synchronization of tumor and normal cells from GI to multiple cell cycles by lovastatin. Cancer Res., 51, 3602-3609.
19. Rubins, J.B., Greatens, T., Kratzke, R.A., Tan, A.T., Polunovsky, V.A. and Bitterman, P. (1998) Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med., 157, 1616-1622.
20. Jones, K.D., Couldwell, W.T., Hinton, D.R., Su, Y., He, S., Anker, L. and Law, R.E. (1994) Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun., 205, 1681-1687.
21. Vitale, M., Di Matola, T., Rossi, G., Laezza, C., Fenzi, G. and Bifulco, M. (1999) Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology, 140, 698-704.
22. Wong, W.W.L., Tan, M.M., Xia, Z., Dimitroulakos, J., Minden, M.D. and Penn, L.Z. (2001) Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res., 7, 2067-2075.
23. van de Donk, N.W.C.J., Kamphuis, M.M., Lokhorst, H.M. and Bloem, A.C. (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 16, 1362-1371.
24. Wong, W.W.L., Dimitroulakos, J., Minden, M.D. and Penn, L.Z. (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 16, 508-519.
25. 1 checkpoint. Oncogene, 19, 6082-6090.
26. Dimitroulakos, J., Ye, L.Y., Benzaquen, M., Moore, M.J., Kamel-Reid, S., Freedman, M.H., Yeger, H. and Penn, L.Z. (2001) Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin. Cancer Res., 7, 158-167.
27. Wang, I.K., Lin-Shiau, S.Y. and Lin, J.K. (2000) Induction of apoptosis by lovastatin through activation of caspase-3 and DNAse II in leukaemia HL-60 cells. Pharmacol. Toxicol., 86, 83-91.
28. Frassanito, M.A., Silvestris, F., Silvestris, N., Cafforio, P., Camarda, G., Iodice, G. and Dammacco, F. (1998) Fas/Fas ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clin. Exp. Immunol., 114, 179-188.
29. Dimitroulakos, J., Nohynek, D., Backway, K.L., Hedley, D.W., Yeger, H., Freedman, M.H., Minden, M.D. and Penn, L.Z. (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood, 93, 1308-1318.
30. Silvestris, F., Cafforio, P., Tucci, M., Del Prete, A. and Dammacco, F. (2000) VEINCTR-N, an immunogenic epitope of Fas (CD95/APO-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease. Mol. Med., 6, 509-526.
31. Silvestris, F., Cafforio, P., Frassanito, M.A., Tucci, M., Romito, A., Nagata, S. and Dammacco, F. (1996) Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. AIDS, 10, 131-141.
32. Stirewalt, D.L., Appelbaum, F.R., Willman, C.L., Zager, R.A. and Banker, D.E. (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk. Res., 27, 133-145.
33. Du, C., Fang, M., Li, Y., Li, L. and Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33-42.
34. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
35. Graaf, M.R., Richel, D.J., van Noorden, C.J.F. and Guchelaar, H.J. (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev., 30, 609-641.
36. van de Donk, N.W.C.J., Kamphuis, M.M.J., van Kessel, B., Lokhorst, H.M. and Bloem, A.C. (2003) Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood, 102, 3354-3362.
37. Denoyelle, C., Vasse, M., Korner, M., Mishal, Z., Gannè, F., Vannier, J.P., Soria, J. and Soria, C. (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis, 22, 1139-1148.
38. Kozar, K., Kaminski, R., Legat, M., Kopec, M., Nowis, D., Skierski, J.S., Koronkiewicz, M., Jakobisiak, M. and Golab, J. (2004) Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol., 24, 1149-1157.
39. Siegel-Axel, D.I. (2003) Cerivastatin: a cellular and molecular drug for the future? Cell. Mol. Life Sci., 60, 144-164.
40. Hatanaka, T. (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet., 39, 397-412.
41. Hamelin, B.A. and Turgeon, J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci., 19, 26-37.
42. Pruitt, K. and Der, C.J. (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett., 171, 1-10.
43. Holstein, S.A. and Hohl, R.J. (2001) Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leukemia Res., 25, 651-660.
44. Hallek, M., Bergsagel, P.L. and Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3-21.
45. Frassanito, M.A., Cusmai, A., Piccoli, C. and Dammacco, F. (2002) Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br. J. Haematol., 118, 157-165.
46. Ryan, J., Hardeman, E.C., Endo, A. and Simoni, R.D. (1981) Isolation and characterization of cells resistant to ML236B (compactin) with increased levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Biol. Chem., 256, 6762-6768.
47. Mo, H. and Elson, C.E. (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med., 229, 567-585.
48. Engels, I.H., Stepczynska, A., Stroh, C., Lauber, K., Berg, C., Schwenzer, R., Wajant, H., Janicke, R.U., Porter, A.G., Belka, C., Gregor, M., Schulze-Osthoff, K. and Wesselborg, S. (2000) Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene, 19, 4563-4573.
49. Tang, D., Lahti, J.M. and Kidd, V.J. (2000) Caspase-8 activation and Bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J. Biol. Chem., 275, 9303-9307.
50. Chan, K.K.W., Oza, A.M. and Siu, L.L. (2003) The statins as anticancer agents. Clin. Cancer Res., 9, 10-19.
51. Minden, M.D., Dimitroulakos, J., Nohynek, D. and Penn, L.Z. (2000) Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk. Lymphoma, 40, 659-662.